Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serpin family A member 12 (SERPINA12), commonly called vaspin, is a secreted serine protease inhibitor predominantly produced in visceral adipose tissue. It functions as an adipokine and specifically inhibits the serine protease kallikrein 7, protecting insulin from degradation and thereby modulating insulin sensitivity and glucose homeostasis. Vaspin also interacts with the cell surface chaperone protein GRP78 (heat shock protein family A member 5), initiating intracellular signaling via AKT, AMPK, and MAPK pathways. SERPINA12 has established roles in lipid metabolism, inflammation, and may influence angiogenesis and cell proliferation. Dysregulation of SERPINA12/vaspin is associated with obesity, insulin resistance, type 2 diabetes, and several endocrine pathologies. Serum vaspin/ SERPINA12 concentrations are under investigation as biomarkers for metabolic diseases[1][2][3].
Inhibition of target serine proteases (especially kallikrein 7) to protect insulin from degradation and modulate metabolic homeostasis; Intracellular signaling modulation via binding to GRP78/Heat shock protein family A member 5 on the cell surface, activating kinase pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serpin family A member 12 (SERPINA12).